Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation

seekingalpha2022-01-31

In a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a planned Phase 2 study of KB109 in patients with chronic obstructive pulmonary disease (COPD) study ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Xyl
    2022-01-31
    Xyl
    [Smile] 
  • CET 789
    2022-01-31
    CET 789
    Great...
  • analyst
    2022-01-31
    analyst
    Stonk la
  • Shandon
    2022-01-31
    Shandon
    Ok
  • Kk Trader
    2022-01-31
    Kk Trader
    Ok
  • TTrade
    2022-01-31
    TTrade
    A like pls. Have a good day. 
Leave a comment
10